Original Article

JVS

Mycobacterium vaccae induces a strong Th1 response that subsequently declines in C57BL/6 mice

Lijiao Zhang[1,2], Yanlong Jiang[1], Ziyin Cui[1], Wentao Yang[1], Limin Yue[1], Yingcong Ma[1], Shaohua Shi[1], Chunfang Wang[1], Chunfeng Wang[1,*], Aidong Qian[1,*]

[1]*College of Animal Science and Technology, Jilin Agricultural University, Changchun 130118, China*
[2]*College of Biological Science, Changchun Teacher University, Changchun 130032, China*

Mycobacterium (*M.*) *vaccae* is a fast-growing species of saprophytic bacteria that is widely distributed. To understand the host immune responses induced by *M. vaccae* isolated from bovine submaxillary lymph nodes, C57BL/6 mice were infected with reference strain *M. bovis* Bacillus Calmette-Guérin (BCG) and isolated *M. vaccae* using intraperitoneal injections. Comparison of the bacterial replication and organ pathology between *M. vaccae* and *M. bovis* BCG revealed that *M. vaccae* was more malignant than *M. bovis* in mice. We also demonstrated that serum from the *M. vaccae*-infected mice contained a higher expression level of gamma-interferon (IFN-γ), tumor necrosis factor alpha, monocyte chemoattractant protein-1, interleukin (IL)-4, IL-12, IL-10 and transforming growth factor beta than did the other groups, especially after week 4. Furthermore, when the numbers of CD3$^+$CD4$^+$IFN-γ$^+$ and CD3$^+$CD4$^+$IL4$^+$ cells in the infected mice were observed by flow cytometry, we found that a powerful T helper 1 (Th1) response was induced by *M. vaccae* infection, which was associated with the emergence of CD3$^+$CD4$^+$IFN-γ$^+$ cells. However, the Th1 response declined over time, which was associated with appearance of the CD4$^+$CD25$^+$FoxP3$^+$ and CD4$^+$CD25$^+$CD152$^+$Treg cell reaction. In addition, a strong Th2 response was found. Finally, we found that *M. vaccae* infection increased the production of type I IFNs, which was associated with a reduced Th1 response.

Keywords: *Mycobacterium bovis* Bacillus Calmette-Guérin, *Mycobacterium vaccae*, Th1 cells response, regulatory T cell

Introduction

Mycobacterial species other than those belonging to the *Mycobacterium* (*M.*) *tuberculosis* complex or *M. leprae* are known as nontuberculous mycobacteria (NTM), environmental mycobacteria, or atypical mycobacteria [14]. NTM are ubiquitous in the environment and induce opportunistic infections that can produce a wide range of diseases, and a large number of NTM have been isolated from mammals [20]. As opportunists, NTM cause acute or chronic infections in patients with cystic fibrosis [1], cancer [4], HIV [21] and immunosuppression [18]. In humans, NTM comprise an important clinical problem associated with significant morbidity, and their occurrence is increasing worldwide [35]. Accordingly, researchers are searching for an immunogenetic factor that will illuminate susceptibility to non-tuberculous mycobacterial disease. To identify new therapeutic targets and enable rational vaccine design, increased understanding of the molecular and cellular host defense mechanisms providing protective immunity against NTM is needed [17]. However, most studies of NTM conducted to date have focused on epidemiological investigations [35], drug sensitivity [11] and laboratory diagnosis [33]. Indeed, there have been few investigations of host immune mechanisms following infection or the reasons for which NTM can persist in the host. Therefore, there is an urgent need to clarify the infection mechanisms of NTM.

Innate immune responses play an important role in bacterial destruction; however, the chronic nature and high incidence of *M. tuberculosis* with low levels of CD4$^+$ T cells indicates the importance of adaptive immune effectors [17,29]. T helper 1 (Th1) cell-mediated immune responses can effectively remove *Mycobacterium* [26]. Following infection, a central control step against mycobacteria is activation of CD4$^+$ T helper 1 cells, which produce effector cytokines such as tumor necrosis factor alpha (TNF-α) and gamma-interferon (IFN-γ) [3]. The Th1 cytokines, such as interleukin (IL)-12, IL-23, IL-18 and TNF-α,

are essential to inhibition of bacterial growth and restrained dissemination [12,24]. An increased risk for disseminated NTM disease in humans includes defects in IL-12 [2], IFN-γ [10] or, more recently, interferon regulatory factor-8 (IRF-8) [16]. Some studies have suggested that the expression of immunosuppressive cytokines such as IL-10 and transforming growth factor beta (TGF-β) may be useful to inhibit infection with highly virulent bacterial strains, which are usually susceptible to these cytokines [9]. The active Th1 response and reduced Th2 responses in infected humans or mice protect the body [23]. Although type I IFNs are important to reducing the Th1 immunity during *M. tuberculosis* infection [25], no studies of type I IFNs during NTM infection have been conducted. Researchers have demonstrated a significant role of CD4$^+$CD25$^+$ regulatory T cells, which are associated with Th1 responses, during *M. tuberculosis* infection [27]. However, it is necessary to further investigate the function of CD4$^+$ CD25$^+$ regulatory T cells during NTM infection.

Most nosocomial NTM outbreaks are caused by rapidly growing mycobacteria [7,8], including *M. vaccae*. *M. vaccae* was first isolated and named by Bönicke and Juhasz [6] in 1963 using the Latin word for cattle (vaccae) because of its strong connection with cows. *M. vaccae* has been reported as a cause of clinical diseases, such as bovine nodular thelitis, in cattle [22,32]. Moreover, this organism was found to be connected with soft tissue infections and pulmonary disease in four people at the University of Texas MD Anderson Cancer Center (Houston, USA) [15]. Studies have shown an immuno-protective effect of heat-killed *M. vaccae* on *M. tuberculosis*-infected mice. Heat-killed bacteria can induce a Th1 response, inhibit the effects of Th2 response, and increase the levels of CD4$^+$T cells and the expression of cytokines [13]. However, few studies have investigated immune mechanisms during a live *M. vaccae* infection. In this study, we isolated a type of *M. vaccae* from bovine submaxillary lymph nodes in the Preventive Veterinary Laboratory (Jilin Agricultural University, China) [37]. The goal of this study was to compare the *M. vaccae* isolated from bovine submaxillary lymph nodes to *M. bovis* BCG in terms of their infection properties and host immune mechanisms.

Materials and Methods

Bacterial cultures

M. bovis Bacillus Calmette-Guérin (BCG) was obtained from the Preventive Veterinary Laboratory (Jilin Agricultural University). *M. vaccae* was isolated from bovine submaxillary lymph nodes in the Preventive Veterinary Laboratory (Jilin Agricultural University) [37] and cultured in supplemented Middlebrook 7H9 Broth medium.

Mice

Specific pathogen-free (SPF) female C57BL/6 mice were bought from Beijing HFK Bioscience, China. Mice were used at six weeks of age. All of the experimental procedures complied with the requirements of the Animal Care and Ethics Committees of Jilin Agriculture University.

Mouse infection

The mice were infected with reference strain *M. bovis* BCG and isolated *M. vaccae* using intraperitoneal injections of 1×10^6 bacilli per animal. At weeks 2, 4, 6 and 8, the bacterial load was measured by plating serial dilutions of organ homogenates onto supplemented Middlebrook 7H9 agar at 37°C, and the samples were enumerated one week later. A total of five animals were infected for each time point.

Histopathology

The lung samples were fixed in 10% formalin buffer for one week, after which the organs were sliced into 5 μm thick sections and stained using hematoxylin and eosin and acid-fast stains as previously described [25].

Lung cell digestion

Lung samples were digested with deoxyribonuclease IV and collagenase XI as previously reported [26,31], after which the digested lungs were pushed through cell strainers (BD Biosciences, USA). The red blood cells were then lysed with ammonium-chloride-potassium lysis buffer.

Flow cytometric characterization

The cell suspensions were incubated with monoclonal antibodies at 4°C for 30 min as previously described [25,31]. Monoclonal antibodies against CD3 (clone 17A2, rat anti-mouse IgG), CD4 (clone GK1.5, rat anti-mouse IgG), CD8 (clone 53-6.7, rat anti-mouse IgG), CD25 (3C7, rat IgM), CD152 (cytotoxic T-lymphocyte-associated protein [CTLA]-4, cloneUC10-4F10-11, hamster anti-mouse IgG), CD11b (Mac-1, clone M1/70, rat anti-mouse IgG), CD11c (clone N418, anti-mouse IgG), CD45R/B220 (RA3-6B2, rat anti-mouse IgG), and Ly-6C/Gr1 (AL-21, rat anti-mouse IgG) (BD Biosciences). The monoclonal antibody data acquisition and analysis were performed by BD FACSCanto flow cytometry (BD Biosciences), and we examined the samples using a BD C6 flow cytometer (BD Biosciences).

Intracytoplasmic cytokine measurement

The cells were stained as previously described and prepared for intracellular staining [25,31]. The cell membranes were permeabilized according to the kit instructions (Fix/Perm kit; BD Pharmingen, USA), after which the cells were stained with antibodies against Foxp3 (MF23, rat anti-mouse IgG), IL-4 (24G2, rat anti-mouse IgG), and IFN-γ (XMG1.2, rat anti-mouse IgG; eBioscience, USA).

Inflammatory cytokine measurement

We collected mouse blood by removing the eyes, placing the blood in centrifuge tubes for 6 h at 37°C, and then centrifuging the samples for 10 min ($1,509 \times$ g). The supernatant serum was collected and frozen at -80°C until analysis for inflammatory cytokines (IFN-γ, TNF-α, monocyte chemoattractant protein [MCP]-1, IL-4, IL-12, IL-10 and TGF-β) using an ELISA kit (BD Biosciences).

Statistical analysis

All statistical analyses were performed using the SPSS 13.0 software (SPSS, USA) and the results were expressed as the means ± the standard deviation (SD). Paired and unpaired t tests were used to compare variances to identify significant differences.

Results

Bacterial loads in mice

The bacterial load was quantified at weeks 2, 4, 6 and 8 after high-dose (1×10^{6} colony-forming unit) intraperitoneal injection. Infection with *M. vaccae* and *M. bovis* BCG resulted in severe lung infection at 2 weeks, but the bacterial number gradually decreased and was completely cleared by week 8. The group infected with *M. vaccae* contained a larger number of bacteria than the *M. bovis* BCG group ($p < 0.001$; panel A in Fig. 1).

Histopathology after injection challenge with isolated *M. vaccae*

The lung histopathology was characterized in mice challenged with *M. vaccae* and *M. bovis* BCG (panels B and C

Fig. 1. Lung histology of *Mycobacterium* (*M.*) *vaccae* and *M. bovis* Bacillus Calmette-Guérin (BCG)-infected mice. (A) Bacterial counts in the lungs at weeks 2, 4, 6 and 8 after infection of mice infected with *M. vaccae* or *M. bovis* BCG. Student's *t*-test *vs.* the *M. bovis* BCG group, **$p < 0.01$, ***$p < 0.001$. (B) Representative lung acid fast staining bacilli two weeks after *M. vaccae* or *M. bovis* BCG infection. (C) Representative lung histopathology in infected animals on weeks 2, 4, 6 and 8 of the infection. H&E stain. 800× (B), 40× (C).

in Fig. 1). *M. vaccae*-infected mice had inflammatory infiltrates with many acid-fast staining bacilli and large aggregates of lymphocytes (panel B in Fig. 1). At week 2, when a larger quantity of bacteria persisted, there was a local inflammatory response in the lungs. By weeks 4 and 6, the moderate-sized lesions had decreased in size. However, at week 8, when *M. vaccae* and *M. bovis* BCG strains were cleared, healthy lung tissue was observed (panel C in Fig. 1).

The number of CD3⁺CD4⁺ and CD3⁺CD8⁺ T cells during *M. vaccae* infection

The number of CD3⁺CD4⁺ and CD3⁺CD8⁺ T cells were also determined. There was a strong influx of CD3⁺CD4⁺ T cells in *M. vaccae*-infected mice (panel A in Fig. 2), with the numbers reaching the highest levels at week 4 relative to the other groups ($p < 0.01$), then declining. However, the *M. bovis* BCG-infected

group did not experience such a rapid decline. There was a rapid influx of CD8 cells, with the highest levels occurring on weeks 6 and 8 of *M. vaccae* infection compared with the other groups ($p < 0.01$; panel B in Fig. 2). These results were consistent with the histopathology analysis at week 2, in which we observed many more lymphocytic lesions in *M. vaccae*- infected mice (panel B in Fig. 1).

The number of CD3⁺CD4⁺IFN-γ⁺ and CD3⁺CD4⁺IL4⁺ cells in the infected mice

To better understand the Th1 response obtained during *M. vaccae* infection, we examined the number of CD3⁺ and CD4⁺ IFN-γ⁺ cells in the *M. vaccae*-infected mice. We found that the number of CD3⁺CD4⁺IFN-γ⁺ cells in the *M. vaccae*-infected mice increased during week 3 and decreased during week 6 (panel C in Fig. 2). Moreover, a strong Th1 response was

Fig. 2. Early infiltration of CD4⁺, CD8⁺ T cells, CD3⁺CD4⁺ IFN-γ⁺ cells and CD3⁺ CD4⁺ IL4⁺ cells in the lungs of mice infected with *M. vaccae* and *M. bovis* BCG. (A) Total number of cells expressing CD3⁺CD4⁺ surface markers. (B) CD3⁺CD8⁺ surface markers in the lungs of mice infected with various strains. (C) Number of CD3⁺ and CD4⁺ IFN-γ⁺ cells in *M. vaccae*-infected mice. (D) Number of CD3⁺ and CD4⁺ IL4⁺ cells in *M. vaccae*-infected mice. The results are expressed as the average ± SEM ($n = 5$ mice) of CD3⁺CD4⁺, CD3⁺CD8⁺ T cells, CD3⁺CD4⁺ IFN-γ⁺ cells or CD3⁺ and CD4⁺ IL4⁺ cells in the lungs. Student's *t*-test *vs.* the normal group, *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$.

associated with the emergence of CD3⁺CD4⁺IFN-γ⁺cells initially induced by *M. vaccae*. In contrast, *M. bovis* BCG induced a Th1 response that did not decline as quickly.

We also evaluated the Th2 response, which was characterized by the emergence of CD3⁺CD4⁺IL4⁺ cells. As shown in panel D in Fig. 2, a decrease in CD3⁺CD4⁺IL4⁺ cells in the *M. vaccae*-infected mice occurred during the third week, while the number of cells increased in the sixth week. *M. bovis* BCG-infected mice did not have an increased Th2 response.

The expression of IFN-γ, TNF-α, MCP-1, IL-4, IL-12, IL-10 and TGF-β in the serum of infected mice

We demonstrated that the serum from the *M. vaccae*-infected mice contained more IFN-γ starting in the first week of infection

and that they had a higher level of IFN-γ in week 4 than the other groups ($p < 0.001$). Further analysis showed similar results for TNF-α and MCP-1, as well as the production of IL-12. Moreover, IL-4, IL-10 and TGF-β were higher in the *M. vaccae*-infected mice than in the *M. bovis* BCG group and the normal group, especially after week 4 ($p < 0.001$; Fig. 3).

Differences between dendritic cells (DCs) and plasmacytoid DCs (pDCs) in the infected mice

The major producers of type I IFNs are DCs and plasmatoid DC cells [26]. As shown in Fig. 4A, we observed an increased number of DCs during *M. vaccae* infection to levels higher than were observed in response to *M. bovis* BCG infection from week 2 to week 4. Similarly, an increased number of pDCs was

Fig. 3. Differential production of IFN-γ, TNF-α, MCP-1, IL-12p40, IL-10 and TGF-β cytokines in the serum of C57BL/6 mice infected with various bacterial strains (*M. vaccae* and *M. bovis* BCG). The levels of IFN-γ, TNF-α, MCP-1, IL-12p40, IL-10 and TGF-β were measured by ELISA. The results are expressed as the means ± SEM (*n* = 5 mice) in the serum. Student's *t*-test *vs.* the normal group, *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$.

observed during *M. vaccae* infection from week 2 to week 8 to levels higher than occurred in response to *M. bovis* BCG infection (panel B in Fig. 4).

## CD4⁺CD25⁺Foxp3⁺ regulatory T cell levels in the infected mice

We evaluated the number of CD4⁺CD25⁺Foxp3⁺ regulatory T cells in the *M. vaccae*-infected mice. We found evidence of a large number of CD4⁺CD25⁺Foxp3⁺ regulatory T cells in the *M. vaccae* group ($p < 0.001$), as well as rapid expression of the cells at week 4 ($p < 0.001$). A smaller number of these cells was

observed in the *M. bovis* BCG group ($p < 0.05$; panel A in Fig. 5).

To further investigate the expression of immunosuppressive Treg cells in the *M. vaccae*-infected mice, we examined mouse CD152 (CTLA-4). The expression level of CD152 can directly or indirectly regulate the level of Treg cells, and it plays a negative regulatory role in the immune response [26]. We found a stronger influx of CD4⁺CD25⁺CD152⁺ T cells during *M. vaccae* infection from week 1 to week 3 than in *M. bovis* BCG-infected and normal mice, but these cells declined after 4 weeks of *M. vaccae* infection in conjunction with a reduced number of CD3⁺CD4⁺ T cells (panel B in Fig. 5). In contrast, *M.*

Fig. 4. Early infiltration of DCs and pDCs in the lungs of mice infected with the *M. vaccae* isolate and *M. bovis* BCG. Lung cells obtained from C57BL/6 mice infected with *M. vaccae* or *M. bovis* BCG and normal mice were assayed for the total number of pDCs (A) and DCs (B) using flow cytometry. The results are expressed as the average ± SEM of ($n = 5$ mice) pDCs or DCs in the lungs. Student's *t*-test *vs.* the normal group, *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$.

Fig. 5. CD4⁺CD25⁺Foxp3⁺ cells in infected mice. Mice infected with *M. vaccae* showed a substantial increase in CD4⁺CD25⁺Foxp3⁺ regulatory T cells in the lungs relative to the *M. bovis* BCG and normal groups (A). Mice infected with *M. vaccae* showed a significant increase in CD4⁺CD25⁺CD152⁺ T cells in the lungs relative to the *M. bovis* BCG and normal groups of mice at 3 weeks, whereas a larger number was observed in *M. bovis* BCG-infected mice beginning at 3 weeks (B). The results are expressed as the mean number ± SEM of CD4⁺CD25⁺Foxp3⁺ or CD4⁺CD25⁺CD152⁺ T cells ($n = 5$ mice) in the lungs. Student's *t*-test *vs.* the normal group, *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$.

bovis BCG-infected mice contained a large number of CD4$^+$CD25$^+$CD152$^+$ T cells after 4 weeks (p < 0.001). Therefore, the decreased expression of CD152 by *M. vaccae*-infected mice led to a lack of CD152 signaling.

Discussion

Over the past few decades, researchers have exerted intense efforts to elucidate the host immune mechanisms activated in response to infection with NTM, but have had limited success [17,29]. *M. vaccae* is a fast-growing species of saprophytic bacteria that is widely distributed [6]. It is interesting to note that most of the patients with pulmonary *M. vaccae* infection had a history of life on cattle farms [15]. However, further studies are needed to investigate the epidemiology, clinical manifestations, and host immune mechanisms of live *M. vaccae* infection because studies conducted to date have focused on heat-killed *M. vaccae*. It is known that heat-killed *M. vaccae* can cause decreased Th2 responses and increased Treg and Th1 responses [19,36], which can protect the host against tuberculosis infection. However, to the best of our knowledge, it is currently unknown if these changes occur following infection with living *M. vaccae*.

In this research, we investigated the host immune responses against live *M. vaccae* infection. The results showed that the isolated *M. vaccae* was clearly more virulent in mice than *M. bovis* BCG, grew much faster in lungs and induced severe lung damage and consolidation, especially during the first 2 weeks of infection. After 2 weeks, the infection and lung pathology slowed due to the protective Th1 response induced by *M. vaccae*, including a high level of TNF-α and IFN-γ production. Furthermore, *M. vaccae* inhibited the Th2 response, including lowering the level of IL-4. Previous studies have shown that heat-killed *M. vaccae* can induce a Th1 response and inhibit the effects of Th2 response [39], which was similar to the results of the present study. However, the Th1 response subsequently declined in conjunction with the emergence of Treg cell response after week 4. There was also decreased production of IFN-γ and TNF-α and evidence of increased Th2 response, which was associated with a high level of IL-4 and differed from previous studies. There are several possible reasons for these differences. Specifically, we utilized live *M. vaccae* administered intravenously at 1×10^6 bacilli per animal. Additionally, we investigated the effects in healthy mice, whereas previous studies evaluated the immune-protective effects of heat-killed *M. vaccae* or *M. tuberculosis* in infected mice that were subjected to multiple immunizations with 10^7 bacilli via tail intravenous injection [38,40]. Therefore, our model reflects those individuals infected with live *M. vaccae* more clearly.

Earlier studies of *M. tuberculosis* hypothesized that the type I IFNs were one type of protection for infected animals [18]. A high level of DCs and pDCs, which are type I IFN-rich sources [5], was observed in the *M. vaccae*-infected group. In the present study, DCs and pDCs showed a significant response to *M. vaccae*. We also evaluated the T-cell response during infection. CD3$^+$CD4$^+$IFN-γ$^+$ cell numbers increased rapidly, but then declined at the fourth week after infection, whereas we observed a rapid increase in CD3$^+$CD4$^+$IL4$^+$ cells and large production of IL-10 or TGF-β. Some immunosuppressive cytokines such as IL-10 and TGF-β have previously been confirmed to negatively influence the production of TNF and IFN-γ during mycobacterial infection [20]; therefore, we observed low inductions of TNF-α and IFN-γ from the fourth week, which were associated with the emergence of a high level IL-10 or TGF-β production. The function of Treg cells, which are characterized as CD4$^+$CD25$^+$FoxP3$^+$ cells [28], during *M. tuberculosis* infections is not yet clear because their role has primarily been evaluated during early immune response to such infections [34]. Treg cells that delay T cell priming are present in infected tissue, and mycobacterial immune recovery of patients with HIV infection disease seems to lead to generation of a large number of Treg cells [30]. However, there has been little research on the function of regulatory T cells during *M. vaccae* infection. The results of the present study indicated that the presence of Treg cells was associated with inhibition of the acquired immune response by a reduction in IFN-γ in *M. vaccae*-infected mice. Furthermore, we determined the number of CD4$^+$CD25$^+$CD152$^+$ cells in *M. vaccae*-infected mice, which was associated with the expression of immunosuppressive Treg cells and was down-regulated by week 4. We believe that the decreased expression of CD152 during *M. vaccae*-infection at week 4 and the coinciding decrease in IFN-γ levels represents a lack of CD152 and fewer activated T cells.

Our study describes the immune processes involved in host defense against infections with *M. vaccae*. Several different immune responses differed compared to heat-killed *M. vaccae* infection, and we demonstrated that the *M. vaccae* isolate was more virulent. Moreover, our study showed several new aspects of the immune response during NTMs infection, which may help improve our understand NTMs and provide a solid basis for treatment strategies.

Acknowledgments

Conflict of Interest

There is no conflict of interest.

References

1. **Aksamit TR, Philley JV, Griffith DE.** Nontuberculous mycobacterial (NTM) lung disease: the top ten essentials. Respir Med 2014, **108**, 417-425.

2. **Altare F, Durandy A, Lammas D, Emile JF, Lamhamedi S, Le Deist F, Drysdale P, Jouanguy E, Döffinger R, Bernaudin F, Jeppsson O, Gollob JA, Meinl E, Segal AW, Fischer A, Kumararatne D, Casanova JL.** Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 1998, **280**, 1432-1435.

3. **Appelberg R, Castro AG, Pedrosa J, Silva RA, Orme IM, Minóprio P.** Role of gamma interferon and tumor necrosis factor alpha during T-cell-independent and -dependent phases of *Mycobacterium avium* infection. Infect Immun 1994, **62**, 3962-3971.

4. **Arlotta A, Cefalo MG, Maurizi P, Ruggiero A, Dodi I, Riccardi R.** Critical pulmonary infection due to nontuberculous mycobacterium in pediatric leukemia: report of a difficult diagnosis and review of pediatric series. J Pediatr Hematol Oncol 2014, **36**, 66-70.

5. **Asselin-Paturel C, Trinchieri G.** Production of type I interferons: plasmacytoid dendritic cells and beyond. J Exp Med 2005, **202**, 461-465.

6. **Bönicke R, Juhasz SE.** Description of new species *Mycobacterium vaccae* no. sp. Zentralbl Bakteriol Parasitenkd Infekt Hyg 1964, **192**, 133-135.

7. **Brown-Elliott BA, Wallace RJ Jr.** Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev 2002, **15**, 716-746.

8. **Daley CL, Griffith DE.** Pulmonary disease caused by rapidly growing mycobacteria. Clin Chest Med 2002, **23**, 623-632, vii.

9. **Dheda K, Booth H, Huggett JF, Johnson MA, Zumla A, Rook GAW.** Lung remodeling in pulmonary tuberculosis. J Infect Dis 2005, **192**, 1201-1209.

10. **Dorman SE, Picard C, Lammas D, Heyne K, van Dissel JT, Baretto R, Rosenzweig SD, Newport M, Levin M, Roesler J, Kumararatne D, Casanova JL, Holland SM.** Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies. Lancet 2004, **364**, 2113-2121.

11. **Egelund EF, Fennelly KP, Peloquin CA.** Medications and monitoring in nontuberculous mycobacteria infections. Clin Chest Med 2015, **36**, 55-66.

12. **Feng CG, Jankovic D, Kullberg M, Cheever A, Scanga CA, Hieny S, Caspar P, Yap GS, Sher A.** Maintenance of pulmonary Th1 effector function in chronic tuberculosis requires persistent IL-12 production. J Immunol 2005, **174**, 4185-4192.

13. **Flynn JL, Chan J.** Immunology of tuberculosis. Annu Rev Immunol 2001, **19**, 93-129.

14. **Gonzalez-Santiago TM, Drage LA.** Nontuberculous mycobacteria: skin and soft tissue infections. Dermatol Clin 2015, **33**, 563-577.

15. **Hambleton S, Salem S, Bustamante J, Bigley V, Boisson-Dupuis S, Azevedo J, Fortin A, Haniffa M, Ceron-Gutierrez L, Bacon CM, Menon G, Trouillet C, McDonald D, Carey P, Ginhoux F, Alsina L, Zumwalt TJ, Kong XF, Kumararatne D, Butler K, Hubeau M, Feinberg J, Al-Muhsen S, Cant A, Abel L, Chaussabel D, Doffinger R, Talesnik E, Grumach A, Duarte A, Abarca K, Moraes-Vasconcelos D, Burk D, Berghuis A, Geissmann F, Collin M, Casanova JL, Gros P.** *IRF8* mutations and human dendritic-cell immunodeficiency. N Engl J Med 2011, **365**, 127-138.

16. **Haug M, Awuh JA, Steigedal M, Frengen Kojen J, Marstad A, Nordrum IS, Halaas Ø, Flo TH.** Dynamics of immune effector mechanisms during infection with *Mycobacterium avium* in C57BL/6 mice. Immunology 2013, **140**, 232-243.

17. **Henkle E, Winthrop KL.** Nontuberculous mycobacteria infections in immunosuppressed hosts. Clin Chest Med 2015, **36**, 91-99.

18. **Hernandez-Pando R, Pavon L, Orozco EH, Rangel J, Rook GA.** Interactions between hormone-mediated and vaccine-mediated immunotherapy for pulmonary tuberculosis in BALB/c mice. Immunology 2000, **100**, 391-398.

19. **Jönsson B, Ridell M, Wold AE.** Non-tuberculous mycobacteria and their surface lipids efficiently induced IL-17 production in human T cells. Microbes Infect 2012, **14**, 1186-1195.

20. **Kobayashi T, Morino E, Takasaki J, Nagahara Y, Sugiyama H.** Nontuberculous mycobacterial osteomyelitis in human immunodeficiency virus-negative patients: a case series. Jpn J Infect Dis 2016, **69**, 149-150.

21. **Koehne G, Maddux R, Britt J.** Rapidly growing mycobacteria associated with bovine mastitis. Am J Vet Res 1981, **42**, 1238-1239.

22. **Lienhardt C, Azzurri A, Amedei A, Fielding K, Sillah J, Sow OY, Bah B, Benagiano M, Diallo A, Manetti R, Manneh K, Gustafson P, Bennett S, D'Elios MM, McAdam K, Del Prete G.** Active tuberculosis in Africa is associated with reduced Th1 and increased Th2 activity *in vivo*. Eur J Immunol 2002, **32**, 1605-1613.

23. **Monack DM, Mueller A, Falkow S.** Persistent bacterial infections: the interface of the pathogen and the host immune system. Nat Rev Microbiol 2004, **2**, 747-765.

24. **Ordway D, Henao-Tamayo M, Harton M, Palanisamy G, Troudt J, Shanley C, Basaraba RJ, Orme IM.** The hypervirulent *Mycobacterium tuberculosis* strain HN878 induces a potent Th1 response followed by rapid down-regulation. J Immunol 2007, **179**, 522-531.

25. **Ottenhoff THM, Verreck FAW, Hoeve MA, van de Vosse E.** Control of human host immunity to mycobacteria. Tuberculosis (Edinb) 2005, **85**, 53-64.

26. **Quinn KM, McHugh RS, Rich FJ, Goldsack LM, de Lisle GW, Buddle BM, Delahunt B, Kirman JR.** Inactivation of CD4+ CD25+ regulatory T cells during early mycobacterial infection increases cytokine production but does not affect pathogen load. Immunol Cell Biol 2006, **84**, 467-474.

27. **Ramsdell F.** Foxp3 and natural regulatory T cells: key to a cell lineage? Immunity 2003, **19**, 165-168.

28. **Hachem R, Raad I, Rolston KVI, Whimbey E, Katz R, Tarrand J, Libshitz H.** Cutaneous and pulmonary infections caused by *Mycobacterium vaccae*. Clin Infect Dis 1996, **23**,

173-175.

29. **Rottman M, Catherinot E, Hochedez P, Emile JF, Casanova JL, Gaillard JL, Soudais C.** Importance of T cells, gamma interferon, and tumor necrosis factor in immune control of the rapid grower *Mycobacterium abscessus* in C57BL/6 mice. Infect Immun 2007, **75**, 5898-5907.

30. **Seddiki N, Sasson SC, Santner-Nanan B, Munier M, van Bockel D, Ip S, Marriott D, Pett S, Nanan R, Cooper DA, Zaunders JJ, Kelleher AD.** Proliferation of weakly suppressive regulatory CD4$^+$ T cells is associated with over-active CD4$^+$ T-cell responses in HIV-positive patients with mycobacterial immune restoration disease. Eur J Immunol 2009, **39**, 391-403.

31. **Shang S, Gibbs S, Henao-Tamayo M, Shanley CA, McDonnell G, Duarte RS, Ordway DJ, Jackson M.** Increased virulence of an epidemic strain of *Mycobacterium massiliense* in mice. PLoS One 2011, **6**, e24726.

32. **Shimizu K, Hirose T, Sato M, Tsukamura M.** Isolation of acid-fast organisms resembling *Mycobacterium vaccae* from a lesion of bovine nodular thelitis. Microbiol Immunol 1977, **21**, 469-472.

33. **Starke JR; Committee on Infectious Diseases.** Interferon-γ release assays for diagnosis of tuberculosis infection and disease in children. Pediatrics 2014, **134**, e1763-1773.

34. **Urdahl KB, Shafiani S, Ernst JD.** Initiation and regulation of T-cell responses in tuberculosis. Mucosal Immunol 2011, **4**, 288-293.

35. **Velayati AA, Farnia P, Mozafari M, Mirsaeidi M.** Nontuberculous mycobacteria isolation from clinical and environmental samples in Iran: twenty years of surveillance. Biomed Res Int 2015, **2015**, 254285.

36. **von Reyn CF, Mtei L, Arbeit RD, Waddell R, Cole B, Mackenzie T, Matee M, Bakari M, Tvaroha S, Adams LV, Horsburgh CR, Pallangyo K; DarDar Study Group.** Prevention of tuberculosis in Bacille Calmette-Guerin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 2010, **24**, 675-685.

37. **Wang C, Qi H, Jiang X, Chen FF, Ma H, Wang C, Qian A.** Molecular differentiation of nontuberculous Mycobacterium isolated from different animals. Appl Mech Mater 2013, **421**, 300-303.

38. **Wang CC, Rook GA.** Inhibition of an established allergic response to ovalbumin in BALB/c mice by killed *Mycobacterium vaccae*. Immunology 1998, **93**, 307−313.

39. **Xu L, Wang Y, Zheng X, Gui X, Tao L, Wei H.** Immunotherapeutical potential of *Mycobacterium vaccae* on *M. tuberculosis* infection in mice. Cell Mol Immunol 2009, **6**, 67-72.

40. **Zuany-Amorim C, Manlius C, Trifilieff A, Brunet LR, Rook G, Bowen G, Pay G, Walker C.** Long-term protective and antigen-specific effect of heat-killed *Mycobacterium vaccae* in a murine model of allergic pulmonary inflammation. J Immunol 2002, **169**, 1492-1499.